A FIRST COST-EFFECTIVENESS ANALYSIS BASED ON REAL LIFE CLINICAL OUTCOMES OF BEVACIZUMAB plus PACLITAXEL COMPARED TO PACLITAXEL AMONG FRENCH PATIENTS WITH HER2-METASTATIC BREAST CANCER IN FIRST LINE OF TREATMENT

被引：0
|
作者：
Petitjean, A. [1 ]
Roze, S. [1 ]
Tehard, B. [2 ]
机构：
[1] HEVA HEOR Sarl, Lyon, France
[2] Roche SAS, Boulogne, France
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.09.2232
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN158
引用
收藏
页码：A737 / A737
页数：1
相关论文
共 50 条
  • [1] The cost-effectiveness of bevacizumab in combination with paclitaxel in first-line treatment of patients with metastatic breast cancer.
    Montero, A. J.
    Gluck, S.
    Lopes, G. D. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [2] Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France
    Petitjean, Audrey
    Smith-Palmer, Jayne
    Valentine, William
    Tehard, Bertrand
    Roze, Stephane
    BMC CANCER, 2019, 19 (1)
  • [3] Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France
    Audrey Petitjean
    Jayne Smith-Palmer
    William Valentine
    Bertrand Tehard
    Stephané Roze
    BMC Cancer, 19
  • [4] COMPARATIVE ANALYSIS OF COST-EFFECTIVENESS BEVACIZUMAB plus PACLITAXEL VERSUS USING ONLY VERSUS PACLITAXEL AS FIRST LINE TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER IN MEXICO PUBLIC INSURANCE (SEGURO POPULAR)
    Arreola Ornelas, H.
    Rosado Buzzo, A.
    Garcia, L.
    Camacho, L. M.
    Lechuga, D.
    VALUE IN HEALTH, 2011, 14 (07) : A448 - A449
  • [5] COMPARATIVE ANALYSIS OF COST-EFFECTIVENESS BEVACIZUMAB plus PACLITAXEL VERSUS USING ONLY VERSUS PACLITAXEL AS FIRST LINE TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER IN THE IMSS (MEXICAN INSTITUTE OF SOCIAL SECURITY)
    Arreola Ornelas, H.
    Rosado Buzzo, A.
    Garcia, L.
    Camacho, L. M.
    Lechuga, D.
    VALUE IN HEALTH, 2011, 14 (07) : A451 - A451
  • [6] Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study
    Delaloge, S.
    Perol, D.
    Courtinard, C.
    Brain, E.
    Asselain, B.
    Bachelot, T.
    Debled, M.
    Dieras, V.
    Campone, M.
    Levy, C.
    Jacot, W.
    Lorgis, V.
    Veyret, C.
    Dalenc, F.
    Ferrero, J. M.
    Uwer, L.
    Kerbrat, P.
    Goncalves, A.
    Mouret-Reynier, M. A.
    Petit, T.
    Jouannaud, C.
    Vanlemmens, L.
    Chenuc, G.
    Guesmia, T.
    Robain, M.
    Cailliot, C.
    ANNALS OF ONCOLOGY, 2016, 27 (09) : 1725 - 1732
  • [7] Cost-Effectiveness Analysis of Bevacizumab plus Paclitaxel versus Bevacizumab plus Capecitabine for HER2-Negative Locally Recurrent or Metastatic Breast Cancer
    Wu, Qiuji
    Wang, Xinyuan
    Zhang, Mengxi
    Liao, Weiting
    Wang, Feng
    Li, Qiu
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (04) : 153 - 159
  • [8] Bevacizumab/paclitaxel as first line therapy for metastatic breast cancer: new schedule in real life
    Cannita, K.
    Paradisi, S.
    Cocciolone, V.
    Rinaldi, L.
    Lanfiuti-Baldi, P.
    Irelli, A.
    Cortellini, A.
    Bruera, G.
    Ricevuto, E.
    Ficorella, C.
    BREAST, 2015, 24 : S41 - S41
  • [9] A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer
    Alberto J. Montero
    Kiran Avancha
    Stefan Glück
    Gilberto Lopes
    Breast Cancer Research and Treatment, 2012, 132 : 747 - 751
  • [10] A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer
    Montero, Alberto J.
    Avancha, Kiran
    Glueck, Stefan
    Lopes, Gilberto
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 132 (02) : 747 - 751
12345